Neurology Central

ECTRIMS 2018: Day 2 Update


Video highlight

You might also like:

Today’s news

Novel treatments for multiple sclerosis on the horizon

Pick of the posters

  • Comi G, Kappos L, Hartung H-P et al. Ozanimod reduces rates of annualized relapse requiring steroids or hospitalization versus interferon B-1a: pooled results from 2 multicenter, randomized, double-blind, Phase III studies in relapsing multiple sclerosis (SUNBEAM and RADIANCE). The authors report results from a post hoc analysis of pooled data from the Phase III SUNBEAM and RADIANCE studies to evaluate the impact of ozanimod on relapses, including severe relapses, in patients with relapsing multiple sclerosis (MS). They concluded that ozanimod reduced the annualized rate of relapses, including predefined severe relapses, versus IFN β-1a 30 μg in patients with relapsing MS; and that the proportions of patients who experienced severe relapse were reduced among those treated with ozanimod versus IFN β-1a 30 μg.
  • Naismith RT, Robinson J, Schobel V. Treatment optimization: are US neurologists using high-efficacy therapies for newly diagnosed RRMS? The objective of this study was to evaluate neurologist perceptions and use of high-efficacy therapies as first-line treatment for newly diagnosed relapsing–remitting MS patients for treatment optimization, as opposed to a treatment-escalation approach. Conclusions of the study revealed that while US neurologists report that they prefer an optimization or aggressive approach to MS management, recent disease-modifying therapy initiations among treatment-naive relapsing–remitting MS patients suggest that the traditional escalation approach continues to dominate clinical practice. A high-efficacy, first-line optimization approach was used slightly, although not significantly, more frequently among neurologists in their first decade of practice. Otherwise, there were no difference in optimization approach by practice site or academic affiliation. Overall, high-efficacy treatments were used in less than one-quarter of relapsing–remitting MS patients recently initiated on their first-line therapy.
  • Block V, Zhao C, Gelfand J, Cree BAC. Validation of the Fitbit Flex2 accelerometer to measure step count in people with Ms during 7 days of continuous remote monitoring in the home environment. The authors wanted to determine the validity of: consumer-grade accelerometer (Fitbit-Flex2) against earlier generation Fitbit-Flex (both wrist worn) and the ActiGraph-GT3X (an accelerometer commonly used in clinical research) to measure step count in people with MS. Preliminary data suggests steps can be determined in people with MS using either the Fitbit-Flex or Flex2. Wrist-worn, consumer-targeted devices can be an alternative to research-grade accelerometers, predominantly for longer-term remote activity monitoring MS (further study is ongoing).
  • Rolla S, Bardina V, Ferrocino I et al. Alterations in gut microbiome are associated with the onset of multiple sclerosis: an Italian pivotal study. The aim of this research was to investigate whether alteration in the composition of the gut microbiota, in terms of species richness, distribution and functional potential, could be associated with the onset of MS, namely the first episode of demyelinization, and its immune system alteration in a small Italian cohort. The authors indicated that gut microbial dysbiosis exist at the onset of MS and could be suggestive of the autoimmune response in the periphery, highlighting the importance of gut microbiota in the etiology of MS. In their Italian cohort, MS onset was associated with changes in a limited number of microbial taxa: a decreased abundance was observed in taxa involved in production of SCFA and in the induction of anti-inflammatory Treg cells.

Picture of the day

Have you spotted this figure anywhere else in Berlin? 

Today at our booth

It was really nice to meet some of the authors that have contributed to us in the past, and to hear about the new research that they’re currently working on! Here at Neuro Central, we are partnered with five journals from Future Medicine and by becoming a member of our website (completely free), you gain FREE access to all of these journals that we are partnered with. Sounds good? We think so too!

Remember to sign up for Neuro Central, or follow our Twitter updates @Neuro_Central

Best of social media #ECTRIMS2018